Calgary, Alberta, November 9, 2009– Orcrist Bio Inc. (ORC), a biotech company developing stem cell-mobilizing pharmaceuticals, congratulates Dr. Linda Pilarski on her receipt of the 2009 ASTech Foundation Outstanding Leadership in Alberta Technology Awa Readmore
Calgary, Alberta, April 6, 2009– Orcrist Bio Inc. (ORC), a biotech company developing stem cell-mobilizing pharmaceuticals, announced today the approval of its Phase I, open-label, single-ascending-dose, safety study of HYC750 in healthy male volunteers Readmore
Calgary, Alberta, February 9, 2009– Orcrist Bio Inc. (ORC), a biotech company developing stem cell-mobilizing pharmaceuticals, announced today that it has filed with the European Competent Authority in Seville, Spain, a Phase I, open-label, single-ascen Readmore
Calgary, Alberta, November 11, 2008– Orcrist Bio Inc. announced today that the U.S. Patent and Trademark Office has approved the issuance of a patent relating to the company's ORC-HYC750 drug candidate for the treatment of chemotherapy-related blood c Readmore
Calgary, Alberta, August 19, 2008– Orcrist Bio Inc., a biotech company developing stem cell-mobilizing pharmaceuticals, has co-authored a peer reviewed publication with Medistem Inc. (OTC BB: MEDS.OB), and collaborators at six academic institutions, pro Readmore
Calgary, Alberta, May 21, 2008– Orcrist Bio Inc. (ORC) and Medistem Laboratories, Inc. (OTCB:MDSM.OB - News) announced today that the companies have entered into a collaborative agreement to co-develop therapies based upon their respective core intellec Readmore
Calgary, Alberta, May 9, 2008– Orcrist Bio Inc. today announced that it has entered into a Royalty and Assignment Agreement with BioMS Medical Corp (TSX:MS) for HYC750, a technology based on hyaluronic acid that has a number of potential therapeutic use Readmore
About Us
Orcrist Bio Inc. is a biotechnology company dedicated to developing and commercializing promising therapeutics for areas in which a clear market opportunity exists.
Our lead program revolves around HYC750, a novel stem cell mobilizer compound that promotes the egress of stem cells and other blood cells from the bone marrow into the blood, from which they can be harvested and applied toward treating chemotherapy-related white blood cell depletion. We are actively looking to add to our pipeline through in-licensing opportunities.
Orcrist is located in Calgary, Alberta. The Company is financed by its founders and by private investors.
Calgary, Alberta, November 9, 2009 – Orcrist Bio Inc. (ORC), a biotech company developing stem cell-mobilizing pharmaceuticals, congratulates Dr. Linda Pilarski on her receipt of the 2009 ASTech Foundation Outstanding Leadership in Alberta Technology Awa 
